Ascendis Pharma (Brazil) Technical Analysis
A1SN34 Stock | BRL 53.35 1.65 3.00% |
As of the 13th of December 2024, Ascendis Pharma shows the risk adjusted performance of 0.0757, and Mean Deviation of 1.08. Ascendis Pharma AS technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Ascendis Pharma Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Ascendis, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to AscendisAscendis |
Ascendis Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Ascendis Pharma AS Technical Analysis
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Ascendis Pharma AS volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Ascendis Pharma AS Trend Analysis
Use this graph to draw trend lines for Ascendis Pharma AS. You can use it to identify possible trend reversals for Ascendis Pharma as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Ascendis Pharma price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Ascendis Pharma Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Ascendis Pharma AS applied against its price change over selected period. The best fit line has a slop of 0.0008 , which means Ascendis Pharma AS will continue generating value for investors. It has 122 observation points and a regression sum of squares at 0.03, which is the sum of squared deviations for the predicted Ascendis Pharma price change compared to its average price change.About Ascendis Pharma Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Ascendis Pharma AS on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Ascendis Pharma AS based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Ascendis Pharma AS price pattern first instead of the macroeconomic environment surrounding Ascendis Pharma AS. By analyzing Ascendis Pharma's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Ascendis Pharma's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Ascendis Pharma specific price patterns or momentum indicators. Please read more on our technical analysis page.
Ascendis Pharma December 13, 2024 Technical Indicators
Most technical analysis of Ascendis help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Ascendis from various momentum indicators to cycle indicators. When you analyze Ascendis charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Risk Adjusted Performance | 0.0757 | |||
Market Risk Adjusted Performance | (0.66) | |||
Mean Deviation | 1.08 | |||
Semi Deviation | 0.8233 | |||
Downside Deviation | 3.43 | |||
Coefficient Of Variation | 1068.18 | |||
Standard Deviation | 3.21 | |||
Variance | 10.3 | |||
Information Ratio | 0.0588 | |||
Jensen Alpha | 0.3344 | |||
Total Risk Alpha | (0.16) | |||
Sortino Ratio | 0.055 | |||
Treynor Ratio | (0.67) | |||
Maximum Drawdown | 25.36 | |||
Value At Risk | (2.94) | |||
Potential Upside | 1.76 | |||
Downside Variance | 11.79 | |||
Semi Variance | 0.6778 | |||
Expected Short fall | (5.35) | |||
Skewness | 5.51 | |||
Kurtosis | 36.18 |
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stocks Directory Find actively traded stocks across global markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies |